D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia

L. Schwarzstein, N. J. Aparicio, D. Turner, E. A. De Turner, F. Premoli, A. V. Schally

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


The effectiveness of D-leucine-6-luteinizing hormone-releasing hormone ethylamide (D-Leu-6-LH-RH-EA) in the treatment of idiopathic normogonadotropic oligoasthenospermia was assessed in 17 patients selected on the basis of at least three previous sperm counts; a history of long-standing infertility; normal serum levels of luteinizing hormone, follicle-stimulating hormone, and testosterone; and lack of any evidence of other pathologic involvement. On testicular biopsy all patients showed hypospermatogenesis or arrest at the spermatid stage with the exception of two with more severe disorders. D-Leu-6- LH-RH-EA was administered intramuscularly for 90 days at a daily dose of 5 μg (four patients), 10 μg (four patients), 20 μg (five patients), and 200 μg (four patients). The results showed no significant improvement in the parameters considered (number of spermatozoa per milliliter, percentage of live and motile spermatozoa, and percentage of forwardly progressive spermatozoa). D-Leu-6-LH-RH-EA does not seem promising for the treatment of oligoasthenospermic patients.

Original languageEnglish (US)
Pages (from-to)332-335
Number of pages4
JournalUnknown Journal
Issue number3
StatePublished - 1978
Externally publishedYes

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia'. Together they form a unique fingerprint.

Cite this